These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

679 related items for PubMed ID: 27300147

  • 1. Safety and efficacy of perampanel in children and adults with various epilepsy syndromes: A single-center postmarketing study.
    Singh K, Shah YD, Luciano D, Friedman D, Devinsky O, Kothare SV.
    Epilepsy Behav; 2016 Aug; 61():41-45. PubMed ID: 27300147
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and safety of adjunctive perampanel in adolescent patients with epilepsy: Post hoc analysis of six randomized studies.
    Piña-Garza JE, Rosenfeld W, Saeki K, Villanueva V, Yoshinaga H, Patten A, Williams B, Malhotra M.
    Epilepsy Behav; 2020 Mar; 104(Pt A):106876. PubMed ID: 31954998
    [Abstract] [Full Text] [Related]

  • 3. Efficacy and safety of perampanel in generalized and focal to bilateral tonic-clonic seizures: A comparative study of Asian and non-Asian populations.
    Nishida T, Lee SK, Wu T, Tiamkao S, Dash A.
    Epilepsia; 2019 Mar; 60 Suppl 1():47-59. PubMed ID: 30869168
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus.
    Strzelczyk A, Willems LM, Willig S, Rosenow F, Bauer S.
    Expert Rev Clin Pharmacol; 2015 Mar; 8(6):733-40. PubMed ID: 26436331
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of perampanel in patients with drug-resistant partial seizures after conversion from double-blind placebo to open-label perampanel.
    Montouris G, Yang H, Williams B, Zhou S, Laurenza A, Fain R.
    Epilepsy Res; 2015 Aug; 114():131-40. PubMed ID: 26088896
    [Abstract] [Full Text] [Related]

  • 7. Long-term safety of perampanel and seizure outcomes in refractory partial-onset seizures and secondarily generalized seizures: results from phase III extension study 307.
    Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Clément JF, Wang X, Bagul M, Gee M, Zhu J, Squillacote D.
    Epilepsia; 2014 Jul; 55(7):1058-68. PubMed ID: 24867391
    [Abstract] [Full Text] [Related]

  • 8. Clinical profiles associated with serum perampanel concentrations in children with refractory epilepsy.
    Ishikawa N, Tateishi Y, Tani H, Kobayashi Y, Kobayashi M.
    Epilepsy Behav; 2019 May; 94():82-86. PubMed ID: 30897534
    [Abstract] [Full Text] [Related]

  • 9. Efficacy, safety, and tolerability of perampanel in Asian and non-Asian patients with epilepsy.
    Tsai JJ, Ikeda A, Hong SB, Likasitwattanakul S, Dash A.
    Epilepsia; 2019 Mar; 60 Suppl 1():37-46. PubMed ID: 30869165
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and Safety of adjunctive Perampanel in a prospective, real-world, Phase IV study in Indian patients aged ≥12 years for Treatment of focal-onset Epilepsy: Study 508.
    Ravat S, Rohatgi A, Kulkarni R, Jabeen SA, Patil B, Dash A, Malhotra M.
    Epilepsia Open; 2024 Jun; 9(3):940-950. PubMed ID: 38124551
    [Abstract] [Full Text] [Related]

  • 11. Perampanel, a selective, noncompetitive α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonist, as adjunctive therapy for refractory partial-onset seizures: interim results from phase III, extension study 307.
    Krauss GL, Perucca E, Ben-Menachem E, Kwan P, Shih JJ, Squillacote D, Yang H, Gee M, Zhu J, Laurenza A.
    Epilepsia; 2013 Jan; 54(1):126-34. PubMed ID: 22905878
    [Abstract] [Full Text] [Related]

  • 12. Perampanel, an AMPA receptor antagonist: From clinical research to practice in clinical settings.
    Tsai JJ, Wu T, Leung H, Desudchit T, Tiamkao S, Lim KS, Dash A.
    Acta Neurol Scand; 2018 Apr; 137(4):378-391. PubMed ID: 29214650
    [Abstract] [Full Text] [Related]

  • 13. Evaluation of adjunctive perampanel in patients with refractory partial-onset seizures: results of randomized global phase III study 305.
    French JA, Krauss GL, Steinhoff BJ, Squillacote D, Yang H, Kumar D, Laurenza A.
    Epilepsia; 2013 Jan; 54(1):117-25. PubMed ID: 22905857
    [Abstract] [Full Text] [Related]

  • 14. Concentration-effect relationships with perampanel in patients with pharmacoresistant partial-onset seizures.
    Gidal BE, Ferry J, Majid O, Hussein Z.
    Epilepsia; 2013 Aug; 54(8):1490-7. PubMed ID: 23772853
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of adjunctive perampanel for the treatment of refractory partial seizures: a pooled analysis of three phase III studies.
    Steinhoff BJ, Ben-Menachem E, Ryvlin P, Shorvon S, Kramer L, Satlin A, Squillacote D, Yang H, Zhu J, Laurenza A.
    Epilepsia; 2013 Aug; 54(8):1481-9. PubMed ID: 23663001
    [Abstract] [Full Text] [Related]

  • 16. First add-on perampanel for focal-onset seizures: An open-label, prospective study.
    Kim JH, Kim DW, Lee SK, Seo DW, Lee JW, Park HJ, Lee SA.
    Acta Neurol Scand; 2020 Feb; 141(2):132-140. PubMed ID: 31745975
    [Abstract] [Full Text] [Related]

  • 17. Lamotrigine adjunctive therapy among children and adolescents with primary generalized tonic-clonic seizures.
    Trevathan E, Kerls SP, Hammer AE, Vuong A, Messenheimer JA.
    Pediatrics; 2006 Aug; 118(2):e371-8. PubMed ID: 16847080
    [Abstract] [Full Text] [Related]

  • 18. Final safety, tolerability, and seizure outcomes in patients with focal epilepsy treated with adjunctive perampanel for up to 4 years in an open-label extension of phase III randomized trials: Study 307.
    Krauss GL, Perucca E, Kwan P, Ben-Menachem E, Wang XF, Shih JJ, Patten A, Yang H, Williams B, Laurenza A.
    Epilepsia; 2018 Apr; 59(4):866-876. PubMed ID: 29574701
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.